Cytosorbents (NASDAQ:CTSO – Get Free Report) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Cytosorbents to post earnings of ($0.12) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Cytosorbents (NASDAQ:CTSO – Get Free Report) last released its earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. The company had revenue of $8.67 million for the quarter, compared to the consensus estimate of $9.29 million. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Cytosorbents Stock Up 3.8 %
Cytosorbents stock opened at $0.84 on Thursday. The company has a quick ratio of 1.51, a current ratio of 1.77 and a debt-to-equity ratio of 0.11. Cytosorbents has a 12-month low of $0.78 and a 12-month high of $4.29. The firm’s fifty day moving average is $0.92 and its 200 day moving average is $1.15. The company has a market capitalization of $45.66 million, a PE ratio of -1.31 and a beta of 0.58.
Analyst Ratings Changes
Get Our Latest Stock Report on Cytosorbents
Cytosorbents Company Profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
See Also
- Five stocks we like better than Cytosorbents
- What is the S&P/TSX Index?
- AMD is Down 35%. Now is the Time to Buy the Dip
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Amazon Stands Tall: New Highs Are in Sight
- What is the Nikkei 225 index?
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.